Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT03581942 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Interventions

DRUG: Ibrutinib
DRUG: Copanlisib

Sponsor

Memorial Sloan Kettering Cancer Center